AMLX
resolvedAmylyx Pharmaceuticals, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Amylyx Pharmaceuticals has been a highly volatile name since the PHOENIX Phase 3 failure for RELYVRIO in ALS, which led to a voluntary market withdrawal of their sole commercial product. A modest 5.2% gap up on very low volume (0.17x average) suggests this is NOT a high-conviction institutional rerating — rather, it likely reflects either slightly better-than-feared financial results (cash runway, expense management) or incremental pipeline optimism. The low volume is a critical signal: Wall Street is not aggressively repositioning here. The bull case for any sustainable rerating would require Amylyx to demonstrate that its pipeline assets — including AMX0035 in other neurodegenerative indications such as Wolfram syndrome or progressive supranuclear palsy (PSP) — have viable paths forward with meaningful readouts. Without a commercial revenue stream, the story is now entirely about cash preservation, pipeline data catalysts, and strategic optionality. Any EPS beat is largely irrelevant; what matters is R&D spend discipline and whether emerging data could support a pivot to new indications. The risk/reward here remains highly binary. With RELYVRIO withdrawn, Amylyx is effectively a clinical-stage company trading on option value. A 5% gap on thin volume does not indicate fundamental repricing — it likely reflects short covering or modest positioning ahead of anticipated data milestones. Investors should watch for substantive pipeline updates, not quarterly financials.
Analyzed by rerate-v2+glm-5.2 · Jul 27, 2026
Catalysts
- Pipeline data readouts from AMX0035 in Wolfram syndrome or other neurodegenerative indications
- Slower cash burn than expected extending runway beyond consensus estimates
- Potential strategic partnership or licensing deal for pipeline assets
- Exploratory signals in PSP or Alzheimer's disease programs that could expand addressable market
- Any path to refile or repurpose RELYVRIO in specific patient subpopulations
Risks
- No commercial revenue stream after RELYVRIO withdrawal — pure cash burn story
- Phase 3 PHOENIX failure creates significant regulatory and credibility overhang for pipeline assets
- Low trading volume gap suggests no institutional conviction — potential head fake
- Cash runway concerns if R&D spend is not meaningfully reduced
- Binary trial outcomes — any negative pipeline readout could send shares significantly lower
- Potential need for dilutive capital raise if runway shortens
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $19.55 | $19.99 | $18.91 | 3.41M |
| Day 2 | $19.73 | $20.21 | $19.05 | 2.07M |
| 📍 Day 3 | $20.75 | $20.94 | $19.31 | 3.55M |
| Day 4 | $20.31 | $20.87 | $19.30 | 1.83M |
| Day 5 | $20.17 | $20.47 | $19.30 | 1.69M |
Signal Breakdown
Gap held — only 0% erased, price maintained gains
Moderate volume decline (51%)
Higher highs with peak close on day 3 — continued buying interest
Minimal drawdown (-0.2%) — price held firm
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026